Skip to main content
Back
CHSYF logo

China Medical System Holdings Limited

Data quality: 100%
Overbought
CHSYF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$1.35
$0.00 (0.00%)
Mkt Cap: 3.28B
Day Range
$0.93 $1.35
52-Week Range
$0.93 $1.64
Volume
110
50D / 200D Avg
$1.35 / $1.31
Prev Close
$1.35

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 2.3 0.4
P/B 0.2 2.9
ROE % 8.6 3.7
Net Margin % 18.1 3.9
Rev Growth 5Y % -1.0 10.0
D/E 0.0 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2028 $1.23
$1.11 – $1.31
 15 B 1
FY2027 $1.01
$0.91 – $1.07
 12 B 1
FY2026 $0.85
$0.76 – $0.90
 10 B 1

Key Takeaways

Revenue declined -1.03% annually over 5 years
Earnings declined -10.45% over the past year
Net margin of 18.13% shows strong profitability
Debt/Equity of 0.04 — conservative balance sheet
Generating 812.64M in free cash flow
P/E of 2.26 — trading at a low valuation

Growth

Revenue Growth (5Y)
-1.03%
Revenue (1Y)7.11%
Earnings (1Y)-10.45%
FCF Growth (3Y)-48.20%

Quality

Return on Equity
8.60%
ROIC6.37%
Net Margin18.13%
Op. Margin19.22%

Safety

Debt / Equity
0.04
Current Ratio6.33
Interest Coverage77.77

Valuation

P/E Ratio
2.26
P/B Ratio0.19
EV/EBITDA0.82
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 7.11% Revenue Growth (3Y) -0.08%
Earnings Growth (1Y) -10.45% Earnings Growth (3Y) -22.27%
Revenue Growth (5Y) -1.03% Earnings Growth (5Y) -16.73%
Profitability
Revenue (TTM) 8.00B Net Income (TTM) 1.45B
ROE 8.60% ROA 7.55%
Gross Margin 71.50% Operating Margin 19.22%
Net Margin 18.13% Free Cash Flow (TTM) 812.64M
ROIC 6.37% FCF Growth (3Y) -48.20%
Safety
Debt / Equity 0.04 Current Ratio 6.33
Interest Coverage 77.77 Dividend Yield 0.03%
Valuation
P/E Ratio 2.26 P/B Ratio 0.19
P/S Ratio 0.41 PEG Ratio -1.51
EV/EBITDA 0.82 Dividend Yield 0.03%
Market Cap 3.28B Enterprise Value 1.26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 8.00B 7.47B 8.01B 9.15B 8.34B
Net Income 1.45B 1.62B 2.40B 3.26B 3.02B
EPS (Diluted) 0.60 0.67 0.98 1.33 1.22
Gross Profit 5.72B 5.42B 6.08B 7.04B 6.25B
Operating Income 1.54B 1.73B 2.71B 3.55B 3.15B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19.21B 18.05B 17.73B 17.75B 15.81B
Total Liabilities 1.66B 1.64B 2.17B 3.02B 2.96B
Shareholders' Equity 17.40B 16.31B 15.52B 14.59B 12.75B
Total Debt 690.43M 860.74M 1.30B 1.81B 1.71B
Cash & Equivalents 2.70B 3.71B 4.31B 4.38B 3.39B
Current Assets 9.30B 8.70B 8.79B 8.83B 7.38B
Current Liabilities 1.47B 1.52B 2.05B 2.88B 2.08B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#695 of 820
23
Value Defensive Investing (Benjamin Graham)
#286 of 708
33

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026